

Formulation and Evaluation of Sustained Release Ambroxol Hydrochloride Microsphere Enriched Syrup

Jaya raja Kumar

*Unit of Pharmaceutical Technology, Faculty of Pharmacy,
Asian Institute of Medicine, Science and Technology (AIMST) University,
Bedong, Semeling Road, Bedong 08100, Kedah, Malaysia.*

Abstract

The main objective of the present work is to formulate taste masked microspheres enriched syrup of ambroxol hydrochloride by an o/w emulsion solvent evaporation method. Such taste-masked formulations have been found to improve the quality of treatment in patients. Ambroxol hydrochloride microspheres help to protect the gastric mucous membrane from drug irritation and to mask its taste. The prepared microspheres enriched syrup were evaluated for particle size, effect of drug and polymer ration and volume of dispersed phase, percentage yield, incorporation efficiency, pH, viscosity, scanning electron microscopy and in vitro drug release. The microspheres produced exhibited good encapsulation efficiencies and rheological properties. The maximum percentage yield of microsphere is around 85.31%. The mean diameters of microspheres were found in range between 4 μ m to 14 μ m. The results of optimized formulations showed a narrow size distribution and smooth surface. In-vitro release showed 72.3% drug release after nine hours.

Key word:

Microspheres enriched syrup, Viscosity, SEM.

INTRODUCTION

Ambroxol is a metabolite of bromohexine which possess mucokinetic and secretolytic properties. It is used in the treatment of respiratory tract disorders such as chronic bronchitis and management of cough. Adverse effects produced such as gastrointestinal disorder, headache, dizziness, sweating, rhinorrhoea, lacrymation and allergic reactions. Due to short biological half-life (4-6 hr), frequent daily dosing (2-3 times) of Ambroxol hydrochloride is required¹. Therefore its formulation in SR microspheres is advantages. The simplest and least expensive way to control the release is to dispense it with in an inert polymeric matrix². Bitter after taste of many drugs which are orally administered often contributes to patient non-compliance in taking medicines. Unfortunately, majority of the drugs have a natural bitter taste that can create a burning feeling in the throat or in the mouth; many active ingredients such as antibiotics possess a strong unpleasant taste³. Administration of bitter drugs orally with acceptable level of palatability is important in case of pediatric and geriatric patients. Thus elimination or reduction of bitterness is an important parameter of product evaluation in oral pharmaceutical formulations. Proven methods for bitterness reductions have resulted in improved palatability of oral pharmaceutical formulations. Various techniques have been developed to improve taste, such as polymeric coating technique⁴, complexation using cyclodextrins⁵ and ion-exchange resin⁶⁻⁸, using known coating or encapsulation⁹ processes with very limited success. Ambroxol syrup is marketed in many countries worldwide for pain relief for sore throat. The local anaesthetic action of ambroxol, a sodium channel blocker, might be effective to relieve symptoms due to inflammation¹⁰⁻¹².

MATERIALS AND METHODS

MATERIALS

Ambroxol hydrochloride was generously supplied as a gift sample by Alembic Ltd. Vadodara, India. Ethyl cellulose and PVP was obtained from Essex, UK, monobasic sodium phosphate and dibasic sodium phosphate Sigma Aldrich, Germany.

METHOD

Preparation of microspheres

The microspheres containing drugs were prepared by quasi emulsion solvent diffusion method using different drug and polymer ratio as shown in Table 1. The inner phase, ethocel and drug were dissolved in dichloromethane, ultra sonication for 10 min. The outer phase prepared by dissolving PVA in distilled water at 40°C for 5 min. The inner phase is cooled then poured drop wise into outer phase. The resultant mixture was stirred by magnetic stirrer for 120 min at 25°C, and filtered to separate the microspheres. The microspheres were dried in an air heated oven at 40 °C, and weighed to determine the yield.

Preparation of microsphere enriched syrup

Weight of microspheres added in the syrup formulation is equivalent to 30 mg of ambroxol hydrochloride, calculated on the basis of assay value. Microspheres prepared above were mixed separately with all the ingredients shown in Table 2. Buffers like monobasic sodium phosphate and dibasic sodium phosphate were added to adjust the formulation to pH 7. A sweetening agent, aspartame and vanilla added as a flavoring agent to all the formulation to improve the palatability.

Table 1: composition of microsphere

Drug ratio (mg)	Polymer ratio (mg)	DCM Solvent (mL)	Yield
30	100	10	85.03±1.52
60	100	10	68.45±1.08
90	100	10	70.61±1.75
30	100	10	85.31±1.41
30	200	10	80.12±1.02
30	300	10	79.46±1.59
30	100	10	85.02±1.12
30	100	20	82.47±1.76
30	100	30	77.05±1.48

Table 2: Composition of microsphere enriched syrup

Composition (% w/v)	F1	F2	F3	F4
Microspheres (ambroxol HCL equivalent)	0.03	0.03	0.03	0.03
Sodium CMC	0.5	1	2	3
Sucrose	33.0	33.0	33.0	33.0
Monobasic sodium phosphate	0.04	0.04	0.04	0.04
Dibasic sodium phosphate	0.42	0.42	0.42	0.42
Sodium benzoate	0.2	0.2	0.2	0.2
Vanilla	q.s	q.s	q.s	q.s
Water (q.s)	Up to 100	Up to 100	Up to 100	Up to 100
pH	6.9	7.0	7.0	6.9

Particle size studies:

Particle size analyses were performed on microspheres by optical microscopy (DN-117M, USA). The results are the average of three analyses. The values (*d*50) were expressed for all formulations as mean size range.

Scanning electron microscopy:

The morphology and size of microspheres were observed by scanning electron microscopy. Prepared microspheres were coated with gold and studied by scanning electron microscopy (Phenoworld) under vacuum at room temperature.

Determination of pH

The pH of the solution and gel was determined using a calibrated pH meter. The readings were taken for average of 3 samples.

Viscosity Studies

The rheological studies were carried out using Brookfield programmable DVII+ Model pro II type (USA). The viscosity of microspheres enriched syrup and the solution were determined at different angular velocities (0.5, 1, 2, 2.5, 4, 5, 10, 20...to 50 rpm) and average of two reading was used to calculate the viscosity.

In vitro drug release study

Microspheres enriched syrup equivalent to 30 mg of ambroxol hydrochloride were transferred to the vessels and subjected to dissolution studies using USP 24 apparatus type II (Paddle method) at 50 rpm/min with 900 ml of dissolution medium at 37.5 ± 0.1 °C for 9 hr. at 50 rpm. 10 ml of sample was withdrawn after every half hour, and was replaced with an equal volume of fresh dissolution medium. Collected samples were analyzed at 257 nm by

spectrophotometrically. Dissolution data for microspheres in different dissolution medium like 0.1N HCl and pH 6.8 phosphate buffers are used.

RESULT AND DISCUSSION

Viscosity is the resistance to gradual deformation by shear stress. Viscosity is an important parameter in rheology of syrup. If the formulation is viscous enough, it may avoid particle aggregation and delay the drug release for longer period of time which may help in the sustained release of drug delivery. The shear stress increases, the viscosity decreases (0.5, 1, 2, 3% SCMC) as shown in figure 1, However 2% and 3% SCMC not suitable for patients.

Microspheres prepared with different ratio of DCM were irregular in shape, hard and rough in texture. The sizes of the drug loaded microsphere prepared with higher ratio of ethocel were larger and not uniform. The irregularity and ununiformity of granules increases with increase in amount of ethocel used and regular shape of microsphere showed in figure 2 and 3.

The formulations F2 released 72.3% as shown in figure 4, whereas the formulations F3 and F4 released 67.7% and 67.4% respectively at nine hour of *in vitro* drug release due to more viscous of syrup formulation.




Figure 1. Showing the viscosity of profile of microspheres enriched syrup




Figure 2: photograph A and B showing optical microscope view



Figure 3. SEM photography C showing the microsphere shape and photography D showing the appearance of microspheres enriched syrup




Figure 4. Showing the *in vitro* release of formulation

CONCLUSION

Microspheres enriched syrup has been developed to provide oral delivery of ambroxol hydrochloride with taste masked. The microspheres showed sustained release of drug through syrup, indicating better potential of delivery system as compared with plain syrup of ambroxol hydrochloride. If this process can be scaled-up to manufacturing level; this technology has the potential to provide the oral ambroxol hydrochloride microspheres enriched syrup with better patient compliance. On the grounds of efficacy and improved patient compliance due to reduced frequency of application, microspheres enriched syrup formulations will have significantly better role in treatment of chronic bronchitis and management of cough.

REFERENCE:

1. Indian Pharmacopoeia, 2007, 2, 701-02.
2. Leon Shargel, Andrew B.C, Yu., Applied Biopharmaceutics and Pharmacokinetics, 3rd edn, 238-246
3. S. Harmik, S. Yasmin, K. K. Roop. Taste masking technologies in oral pharmaceuticals: Recent developments and approaches. Drug. Dev. Ind. Pharm., 2004, 30: 429-448.
4. G. A. Meyer, T. B. Mazer. Prolamine coatings for tastemasking. U.S. Patent No, 5599556. 1997. 11.
5. V. R. Sinha, Amita Nanda, Rachna Kumria. Cyclodextrins as sustained-release carriers. Pharm. Tech., 2002, 26: 36-60.
6. W. J. Irwin, R. Mchale, P. J. Watts. Drug delivery by ion exchange resin-part VII. Release of acidic drugs from anionic exchange resinates complexes. Drug. Dev. Ind. Pharm., 1990, 16: 883-898.
7. Lyn Hughes. Ion exchange resins unique solutions to formulation problems. Pharm. Tech., 2004, 20-25.
8. M. V. Chaubal. Synthetic polymer-based ion exchange resins, excipients & actives. Drug Dev. Tech., 2001, 3: 6-8.
9. Fini, Adamo, Orienti, *et al.* The role of chitosan in drug delivery: current and potential applications. Am. J. Drug. Del., 2003, 1: 43-59.
10. Weiser T, Wilson N: Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na⁽⁺⁾ channels by the secretolytic ambroxol. Mol. Pharmacol. 2002, 62:433-8.
11. Gaida W, Klinder K, Arndt K, Weiser T: Ambroxol, a Nav1.8-preferring Na⁽⁺⁾ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology. 2005, 49:1220-7.
12. Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na⁽⁺⁾ channels by the secretolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2009, 630:19-28.